Drug Trial Radar · NCT06279533
Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules
Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Feb 27, 2024
Primary completion
Dec 17, 2024
Study completion Dec 17, 2024
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is divided into two parts: the safety, tolerability, pharmacokinetic profiles of LV232 capsules after multiple ascending doses (hereinafter referred to as "PK characteristics of multiple ascending doses study ") and food effect study (hereinafter referred to as "FE study"). A total of 48 subjects are planned to be enrolled. The two parts of the study can be carried out simultaneously, and there is no order requirement.
Conditions
- Healthy Subjects
Interventions
LV232/PlaceboDrug
Drug: LV232 15mg Group: 6 subjects will receive LV232 15mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally. Drug: LV232 40mg Group: 6 subjects will receive LV232 40mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally. Drug: LV232 60mg Group: 6 subjects will receive LV232 60mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.
LV232Drug
Drug: LV232 20mg Group: 12 subjects will receive LV232 20mg, orally Drug: LV232 60mg Group: 12 subjects will receive LV232 60mg, orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- TmaxTime frame: Calculated using concentration data collected from predose to 72 hours postdose
- CmaxTime frame: Calculated using concentration data collected from predose to 72 hours postdose
- T1/2Time frame: Calculated using concentration data collected from predose to 72 hours postdose
- AUC0-tTime frame: Calculated using concentration data collected from predose to 72 hours postdose
- AUC0-24hTime frame: Calculated using concentration data collected from predose to 24 hours postdose
- AUC0-∞Time frame: Calculated using concentration data collected from predose to 72 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.